Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth
Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions
Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease
The new API plant is set up to meet all domestic and international regulatory standards and will manufacture niche molecules that have a global requirement
One thousand times more soluble than L-cystine at neutral pH
Capnopharm’s new CapnoPen is the first PIPAC nebulizer to obtain CE marking under the new MDR regulation 2017/745
Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22
Operating EBITDA increased by 21% to INR 181 crores in Q4 FY23
Acquisition enhances Freenome's product portfolio, including autoantibody platform with additional biomarkers important in cancer detection
Leading Research-driven Pharma Company Combats Antibiotic Resistance and Demonstrates Innovation in Medical Solutions
Subscribe To Our Newsletter & Stay Updated
